ClinicalTrials.gg
CompletedNCT06975514Updated Jun 29, 2026

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

A Phase 3 interventional study of YZJ-1139 and Zolpidem in Insomnia Disorder, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 16 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Enrollment
115th of 162
61 · median 88
Started
2025
with 17 others
Phase 3
7 of 198
1 open now
Registered
153rd of 198
by date
Lead sponsor
9 of 198
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 115th largest by enrollment of the 162 interventional ones that give a count, is one of 18 that started in 2025, is one of 7 in phase 3, and was the 153rd registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

03

Conditions studied

  • Insomnia Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, aged ≥ 18 to \< 65 years.
  2. Meet the clinical diagnostic criteria for insomnia disorder as defined in ICSD-3 criteria.
  3. sTSO ≥ 30 min for at least 3 nights per week and/or sWASO ≥ 60 min for at least 3 nights per week within 4 weeks prior to screening.
  4. Able to recognize 26 English letters and score indicats no cognitive impairment.
  5. During the run-in period and on Day 1 of the treatment period, sTSO ≥ 30 min for at least 3 nights in the last 7 sleep diaries and/or sWASO ≥ 60 min for at least 3 nights out of 7 nights as confirmed by the sleep diary prior to PSG monitoring.
  6. PSG results for 2 consecutive nights during the run-in period should meet the following conditions:

    1. The mean LPS ≥ 30 min for 2 nights and ≥ 20 min for any one night; And/or the mean WASO ≥ 60 min for 2 nights, and ≥ 45 min either night.
    2. The mean SE ≤ 85% for 2nights, with the SE ≤ 87.5% for both nights .
  7. ISI score ≥ 15 at screening and on Day 1 of the treatment period .
  8. Have a bedtime between 9 p.m. and 1 a.m., wake up between 5 a.m. and 10 a.m., and stay in bed for 6.5 to 9 hours for at least 5 nights in the last 7 sleep diaries as confirmed by the sleep diary prior to PSG monitoring during the run-in period and on Day 1 of the treatment period.
  9. Reproductive-age male and female participants must agree to use effective measures from the screening visit through at least 30 days after the last dose of double-blind study treatment, and must not be planning to become pregnant or donate sperm/eggs during this period.
  10. Understand the study procedures and contents, voluntarily participate in the clinical study and sign the written Form, have good compliance during participation in the study, and are willing to attend the visits.

Exclusion criteria

Exclusion Criteria:

  1. to YZJ-1139 tablets or zolpidem or to their .
  2. Have serious endocrine diseases, hematological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, liver and kidney diseases, diseases, impaired respiratory function or other related diseases, or have other medical history that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
  3. Have insomnia disorder due to other causes such as chronic pain, headache, eczema, neurodermatitis, allergic rhinitis, and serious dermatitis (difficulty sleeping due to physical reasons, difficulty falling asleep due to medical reasons).
  4. Current or previous history of psychiatric or neurological disease such as epilepsy, schizophrenia, bipolar mental disorder, neurodevelopmental retardation, and cognitive disorder, or previous history of other mental illness that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
  5. Previous history of sleep-related respiratory disorders including obstructive sleep apnea (with or without continuous positive airway pressure [CPAP] therapy), periodic limb movement disorder, myasthenia gravis, restless legs syndrome, circadian rhythm sleep disturbances, narcolepsy or other sleep disorders: subjects with restless legs syndrome which is diagnosed by relevant diagnostic and treatment guidelines should be excluded. Those who have been cured of the above diseases can be enrolled.
  6. Have previous complex sleep behaviors, such as sleep driving, sleep eating, and sleep phone calls.
  7. Have nocturia increased caused by urinary tract infection, urinary tract injury or prostatic disorder.
  8. Hyperthyroidism.
  9. History of alcohol abuse (defined as regular daily alcohol consumption exceeding the following criteria: approximately 720 mL of beer, or 240 mL of wine, or 60 mL of liquor) within the past 6 months.
  10. Regular daily consumption of excessive tea and coffee drinks (defined as consumption of > 4 cups of caffeinated beverages or > 400 mg of caffeine per day), or daily habituation to drinking caffeinated beverages beyond 18:00.
  11. Exclusion Criteria: Smokers who have smoked more than 10 cigarettes per day within 6 months prior to screening or smokers who are unable to refrain from falling asleep.
  12. Have any lifestyle that interferes with the study process or may interfere with sleep: for example, there will be travels across 3 or more time zones (mainland China is considered as 1 time zone) within the next 2 weeks or during the study period, or there will be shift work (night and daytime shift).
  13. History of drug abuse within the past 2 years, or positive urine drug screening for any indicator; history of drug taking or addiction, which is known through questioning.
  14. Have received any hypnotics, antidepressants, antipsychotic drugs, anticholinergics, memory-enhancing drugs, antihistamines, centrally acting analgesics, centrally acting muscle relaxants, central nervous system stimulants, inducers, CYP3A inhibitors, traditional Chinese medicines and traditional Chinese medicinal products with sleep-improving effects, or any other therapies for insomnia disorder within 1 week prior to the run-in period or within 5 half-lives of the product, whichever is longer.
  15. Plan to undergo surgery during the study.
  16. Depression: Hamilton Depression Scale (HAMD) score ≥ 18; anxiety: Hamilton Anxiety Scale (HAMA) score ≥ 14.
  17. Suicidal ideation with or without plan at screening or within 6 months prior to screening (score ≥ 3 on item 3 [suicide] of HAMD, or select "Yes" on item 3, 4 or 5 of suicidal ideation subscale of C-SSRS), or have any suicidal behavior in the past 10 years (as assessed by the suicidal ideation subscale of C-SSRS).
  18. at screening shows interval prolongation (QTcF > 450 ms, QTcF=QT/(RR\^0.33)).
  19. or ALT > 2 × the (ULN), or Cr > 1.5 × ULN.
  20. Known to be (HIV) antibody positive at screening.
  21. Apnea-hypopnea index [AHI] or periodic limb movement index [PLMI] > 10 times/hour detected by PSG monitoring during the run-in period.
  22. Unable to avoid vaccination within 1 month prior to screening.
  23. Enrolled in another clinical trial and used any investigational drug within 1 month or 5 half-lives (whichever is longer) prior to the run-in period, or participation in another investigational trial at the same time during this trial.
  24. Previously participated in any clinical trial of YZJ-1139; or treated with other orexin receptor antagonists of appropriate amount and sufficient duration and who, in the opinion of the investigator, have failed treatment due to efficacy or safety.
  25. Pregnant or lactating women.
  26. Have other conditions that make the subject unsuitable for participation in the clinical study in the opinion of the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    YZJ-1139 group

    Drug: YZJ-1139

  • Active comparator
    Zolpidem group

    Drug: Zolpidem

Interventions

  • YZJ-1139 20mg tablets, once daily in the evening

  • Zolpidem 10mg tablets, once daily in the evening

06

What researchers measure

Primary outcomes

  1. Change from baseline of Mean Objective Wake After Sleep Onset (WASO)

    WASO is defined as minutes of wake from the onset of persistent sleep until lights on as measured by polysomnography (PSG).

    Time frame: Baseline, Day 1/Day 2, Day 27/Day 28

  2. Change from baseline of Mean Objective Sleep Efficiency (SE)

    SE is defined as percentage of time spent in bed asleep, calculated as total sleep time (TST) divided by interval from lights off until lights on as measured by PSG, multiplied by 100.

    Time frame: Baseline, Day 1/Day 2, Day 27/Day 28

  3. Change from baseline of Mean Objective Total Sleep Time (TST)

    TST is defined as total sleep time measured by PSG.

    Time frame: Baseline, Day 1/Day 2, Day 27/Day 28

  4. Change from baseline of Mean Objective Latency to Persistent Sleep (LPS)

    LPS is defined as latency to persistent sleep measured by PSG.

    Time frame: Baseline, Day 1/Day 2, Day 27/Day 28

Secondary outcomes

  1. Change from baseline of Mean Subject Wake After Sleep Onset (sWASO)

    sWASO is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Week1, Week 4

  2. Change from baseline of Mean Subject Sleep Efficiency (sSE)

    sSE is defined as percentage of time spent in bed asleep, calculated as subject total sleep time (sTST) divided by interval from lights off until lights on, multiplied by 100.

    Time frame: Baseline, Week1, Week 4

  3. Change from baseline of Mean subject Total Sleep Time (sTST)

    sTST is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Week1, Week 4

  4. Change from baseline of Mean Subjective Time to Sleep Onset (sTSO)

    sTSO is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Week1, Week 4

  5. Change from baseline of Mean Subjective Number of awakenings (sNAW)

    sNAW is self-reported sleep outcome measured by subject diary data, collected daily and analyzed at appropriate intervals.

    Time frame: Baseline, Week1, Week 4

  6. Change from baseline of Sleep structure (wakefulness, N1, N2, N3, rapid eye movement sleep [REM], non-rapid eye movement sleep [NREM])

    Wakefulness, N1, N2, N3, REM, NREM are measured by PSG in minutes, and expressed as the percent change from time spent in bed (TIB) and TST.

    Time frame: Baseline, Day 1/Day 2, Day 27/Day 28

  7. Change from baseline of Sleep structure (REM latency, number of awakenings [NAW], arousal index for REM and NREM)

    REM latency, NAW and the arousal index for REM and NREM are measured by PSG.

    Time frame: Baseline, Day 1/Day 2, Day 27/Day 28

  8. Change from baseline in the mean subjective sleep quality score

    Subjective sleep quality score is a self-report assessment of participant perception of the effects of a medication on their sleep. Higher score indicated severe insomnia problem.

    Time frame: Baseline, Week1, Week 4

  9. Change from baseline in the ISI score

    Insomnia Severity Index is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Higher score indicated severe insomnia problem.

    Time frame: Baseline, Day15 and Day 28

  10. Percentage of participants on each scale of Global Impression of Insomnia (PGI-I) each item

    the PGI-I was a self-report assessment of participant perception of the effects of a medication on their sleep. The PGI-I had 3 items related to study medication effects (a) helped/worsened sleep, (b) decreased/increased time to fall asleep, (c) increased/decreased total sleep time, and 1 item related to perceived appropriateness of study medication strength. The first 3 items were answered on a 3-point scale (1=positive medication effect, 2=neutral medication effect, 3=negative medication effect) and the last item on a different 3 point scale (medication: 1=too strong, 2=just right, 3=too weak).

    Time frame: Day15 and Day 28

07

Study locations

16 sites
  • Peking University People's Hospital
    Beijing, China
  • ChengDu Second People's Hospital
    Chengdu, China
  • ChongQing Traditional Chinese Medicine Hospital
    Chongqing, China
  • Deyang People's Hospital
    Deyang, China
  • The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital)
    Guangzhou, China
  • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
    Jinan, China
  • The Second Affiliated Hospital Of NanChang University
    Nanchang, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, China
  • ShengJing Hospital Of China Medical University
    Shenyang, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, China
  • SuZhou GuangJi Hospital
    Suzhou, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, China
  • Tianjin Anding Hospital
    Tianjin, China
  • Wuhan No.1 Hospital
    Wuhan, China
  • Yan'an University Xianyang Hospital
    Yan’an, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jul 2025, 3 months.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 3 months is below that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 16, 2025
StartActual
Mar 25, 2025
Primary completionActual
Jul 21, 2025
CompletionActual
Aug 14, 2025
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06975514
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Mar 25, 2025
Primary completion
Jul 21, 2025
Completion
Aug 14, 2025
Last update
Jun 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazamorexant

Start the discussion